Database

Startups

Main Industry
Health Care
Main Product/Service
Caliway’s pipeline includes: CBL‑514, an injectable drug targeting localized fat reduction, cellulite, and Dercum’s disease through adipocyte apoptosis; CBA‑539, a long‑acting injectable for hyperpigmentation and skin aging; and CBF‑520, a chemical entity
Founded Year
2012
Unified Business No.
53942917
Status
Active
Number of Employees
0
Total Paid-in Capital
776,938,930 (NT$)
Location of Company
Taiwan , New Taipei City
Exit Status
Emerging Stock Exchange(2025)、Listing(2024)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Caliway Biopharmaceuticals Co., Ltd. is a clinical‑stage biotech company headquartered in New Taipei City, Taiwan, dedicated to discovering novel small‑molecule therapeutics. The company focuses on aesthetic medicine and chronic inflammatory diseases, aim



More ↓

Similar Companies

HONYA MEDICAL CO., LTD.

1. Cell Therapy
2. Clinical trial
3. MCRcI®
4. MiSaver®

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

GenomeFrontier Therapeutics TW Co., Ltd.

GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and

Ochre Bio Taiwan Ltd

Ochre Bio’s key technology pillars include a Human Discovery Platform (combining patient liver data with gene perturbation atlases), a Human Validation Platform (using perfused livers, diseased tissue slices, and primary cells), and an RNA Therapeutics Pl